E Fund Management (HK)’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$387K Buy
621
+247
+66% +$168K 0.13% 112
2026
Q1
$289K Buy
374
+27
+8% +$20.7K 0.13% 98
2025
Q4
$262K Buy
347
+272
+363% +$185K 0.09% 100
2025
Q3
$42.2K Buy
75
+35
+88% +$19.8K 0.03% 116
2025
Q2
$21K Hold
40
0.02% 112
2025
Q1
$25K Buy
40
+31
+344% +$21.3K 0.02% 106
2024
Q4
$6K Buy
9
+7
+350% +$5.88K ﹤0.01% 118
2024
Q3
$2K Hold
2
﹤0.01% 108
2024
Q2
$2K Buy
+2
New +$1.94K ﹤0.01% 86

Other funds holding REGN

E Fund Management (HK)'s REGN Position: Q2 2026 in Review

E Fund Management (HK) increased its Regeneron Pharmaceuticals (REGN) stake by 66% in Q2 2026, buying an estimated $168K and bringing the position to 621 shares worth $387K. The position accounts for 0.13% of the portfolio, ranked #112.

E Fund Management (HK) first reported a position in REGN in Q2 2024 and has held it in 9 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • E Fund Management (HK) held 621 shares of Regeneron Pharmaceuticals worth $387K as of Q2 2026.
  • E Fund Management (HK) bought 247 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $168K.
  • Regeneron Pharmaceuticals made up 0.13% of E Fund Management (HK)'s portfolio in Q2 2026, its #112 holding.
  • E Fund Management (HK) first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.